News

Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering

  • Tainan, Taiwan, March 07, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the "Company") (NASDAQ: ADVB), a biotechnology company focused on early screening and detection, diagnosis and staging, and treatment of cancer, today announced the closing of its initial public offering (the "Offering") of 1,640,000 shares of common stock (the “Shares”), at a public offering price of $4.00 per share for total gross proceeds of $6.56 million before deducting underwriting discounts and offering expenses. The Shares began trading on the Nasdaq Capital Market on March 6, 2025 under the ticker symbol “ADVB.”
    03/07/2025

IPO Update: Advanced Biomed Finalizes $112 Million U.S. IPO Plan

  • Advanced Biomed has filed proposed terms for a $112 million U.S. IPO. The firm is developing a portfolio of cancer screening technologies for the Chinese market. ADVB has no revenue history, significant operating risks, is thinly capitalized and is seeking a high valuation at the IPO.
    07/19/2023
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

The price of Advanced Biomed Inc. Common Stock (ADVB) is 3.53 and it was updated on 2025-03-13 13:00:28.

Currently Advanced Biomed Inc. Common Stock (ADVB) is in undervalued.

News
    
News

Advanced Biomed sets IPO terms, which could value the biotech at up to $625 million

  • Advanced Biomed Inc. ADVB, has set terms for its initial public offering, in which the Taiwan-based biotechnology company focused on treating cancer is looking to raise up to $125 million. The company said it is offering 25.0 million shares in the IPO, which is expected to price between $4 and $5 a share.
    Wed, Jul. 19, 2023

Advanced Biomed Begins $150 Million U.S. IPO Rollout

  • Advanced Biomed has filed to raise $150 million in a U.S. IPO, although the final amount may vary. The Taiwan-based firm is developing various diagnostic test technologies for cancer and is focused on the Chinese market.
    Tue, May. 23, 2023

Advanced Biomed to raise $150M in IPO

  • Advanced Biomed, a Taiwan-based diagnostics developer, is planning to raise up to $150 million in an initial public offering (IPO).  The company said it intends to list on the Nasdaq under the ticker symbol ‘ADVB', according to documents filed with the Securities and Exchange Commission (SEC) on Monday.
    Tue, May. 23, 2023
Unlock
ADVB Ratings Summary
ADVB Quant Ranking